Multi-centre European Phase I/II clinical trial including personalised treatment of HCC patients.
The planned open label multi-centre European Phase I/II clinical trial is designed to assess safety and biologic efficacy of the HEPAVAC immunotherapy approach in very early and early HCC patients after standard treatment. The trial will start in Spring 2017. The enrolment of patients with newly diagnosed HCC is planned at 6 different European clinical centres with great expertise in treatment of HCC and immunotherapy, in order to ensure enrolment of the target patient number within the first 9-12 months of the trial. The clinical trial will be sponsored by partner INTNA.